Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cem...

Full description

Bibliographic Details
Main Authors: Nick Freemantle, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping, Gerasimos Konidaris, Keith Chan, Andreas Kuznik, Kokuvi Atsou, Emily Glowienka, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel
Format: Article
Language:English
Published: SAGE Publishing 2022-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221105024

Internet

https://doi.org/10.1177/17588359221105024

Similar Items